Intact Investment Management Inc. Buys 306,900 Shares of Pfizer Inc. (NYSE:PFE)

Intact Investment Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 70.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 744,400 shares of the biopharmaceutical company’s stock after purchasing an additional 306,900 shares during the period. Intact Investment Management Inc.’s holdings in Pfizer were worth $19,749,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter valued at $28,000. Gladius Capital Management LP raised its stake in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC bought a new stake in Pfizer in the 4th quarter valued at $31,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PFE shares. Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

PFE opened at $25.60 on Friday. The firm has a market cap of $145.08 billion, a P/E ratio of 18.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s fifty day moving average is $26.26 and its 200-day moving average is $27.17.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.